biologic

Fabrazyme

agalsidase beta

Loss of exclusivityOctober 2015projected — 12-year biologic exclusivity estimate
CompanyGenzyme Corporation

Drug detail

Brand nameFabrazyme
Active ingredientagalsidase beta
Strength5MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 2003
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Fabrazyme patent cliff — loss of exclusivity October 2015 | CliffBio